

Title (en)
TREATMENT OF IMMUNE DISEASES BY MEANS OF THE ANTIBODY-MEDIATED NEUTRALIZATION OF SPECIFIC INTESTINAL BACTERIA

Title (de)
BEHANDLUNG VON IMMUNERKRANKUNGEN DURCH DIE ANTIKÖRPERVERMITTELTE NEUTRALISIERUNG SPEZIFISCHER DARMBAKTERIEN

Title (fr)
TRAITEMENT DE MALADIES IMMUNES PAR NEUTRALISATION MÉDIÉE PAR DES ANTICORPS DE BACTÉRIES INTESTINALES SPÉCIFIQUES

Publication
EP 3830247 A1 20210609 (DE)

Application
EP 19749717 A 20190802

Priority
• DE 102018213030 A 20180803
• EP 2019070910 W 20190802

Abstract (en)
[origin: WO2020025801A1] The invention relates to antibodies or an antigen-binding fragment thereof, wherein the antibody or the antigen-fragment binds to an antigen of the bacterium *Candidatus Savagella* and (i) inhibits the adhesion of the bacterium to intestinal epithelial cells, preferably human intestinal epithelial cells, and/or (ii) depletes the bacterium. The invention additionally provides a medicament comprising the antibody according to the invention or an antigen-binding fragment thereof or comprising an antibody which is produced using the method according to the invention. The invention additionally relates to a kit comprising an antibody according to the invention or an antigen-binding fragment thereof for reducing the Th17 cell proliferation, Th17 cell differentiation, or Th17 cell activity and/or inhibiting the formation of antibodies against endogenous antigens by means of B cells. The kit according to the invention optionally contains an antibiotic. The invention additionally relates to a method for producing an antibody according to the invention, having the steps of: a) immunizing chickens using an immunogenic peptide from an antigen of the bacterium *Candidatus Savagella*; and b) obtaining and purifying the antibodies formed in the chickens or in an egg laid by said chickens. The invention finally relates to a method for producing a medicament according to the invention, having the steps of: a) producing an antibody according to the invention or an anti-binding fragment thereof; and b) formulating the antibody or an antigen-binding fragment thereof as a medicament.

IPC 8 full level
C12N 1/20 (2006.01); **C12N 15/74** (2006.01)

CPC (source: EP KR US)
A61K 45/06 (2013.01 - US); **A61P 3/10** (2018.01 - KR); **A61P 11/06** (2018.01 - KR); **A61P 19/02** (2018.01 - KR); **A61P 35/00** (2018.01 - KR); **C07K 16/1282** (2013.01 - EP KR US); **A61K 2039/505** (2013.01 - KR US); **C07K 2317/11** (2013.01 - EP KR); **C07K 2317/23** (2013.01 - EP KR); **C07K 2317/24** (2013.01 - US); **C07K 2317/33** (2013.01 - KR US); **C07K 2317/76** (2013.01 - US)

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
WO 2020025801 A1 20200206; CN 112867785 A 20210528; DE 102018213030 A1 20200206; DE 102018213030 A8 20200402; EP 3830247 A1 20210609; JP 2021534229 A 20211209; JP 2024105575 A 20240806; KR 20210040998 A 20210414; US 2021198346 A1 20210701

DOCDB simple family (application)
EP 2019070910 W 20190802; CN 201980064592 A 20190802; DE 102018213030 A 20180803; EP 19749717 A 20190802; JP 2021529525 A 20190802; JP 2024079843 A 20240516; KR 20217005682 A 20190802; US 201917265506 A 20190802